Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism

被引：0
|
作者：
Bo Xie
Ying Qiu
Juan Zhou
Dou Du
Haochuan Ma
Jiapeng Ji
Liquan Zhu
Weimin Zhang
机构：
[1] General Hospital of Southern Theater Command,Department of Oncology
[2] PLA,undefined
来源：
Clinical and Translational Oncology | 2022年 / 24卷
关键词：
Lorlatinib resistance; Non-small cell lung cancer; -; Mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2231 / 2240
页数：9
相关论文
共 50 条
  • [41] Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
    Hashida, Shinsuke
    Yamamoto, Hiromasa
    Shien, Kazuhiko
    Miyoshi, Yuichiro
    Ohtsuka, Tomoaki
    Suzawa, Ken
    Watanabe, Mototsugu
    Maki, Yuho
    Soh, Junichi
    Asano, Hiroaki
    Tsukuda, Kazunori
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    CANCER SCIENCE, 2015, 106 (10) : 1377 - 1384
  • [42] Characterization and Sensitization of Non-Small Cell Lung Cancer Cell Line Variants Selected for Resistance to Osimertinib
    Ferguson, P.
    Vincent, M.
    Koropatnick, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S877 - S878
  • [43] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [44] Screening Circular RNAs Related to Acquired Gefitinib Resistance in Non-small Cell Lung Cancer Cell Lines
    Wen, Chunjie
    Xu, Ge
    He, Shuai
    Huang, Yutang
    Shi, Jingjing
    Wu, Lanxiang
    Zhou, Honghao
    JOURNAL OF CANCER, 2020, 11 (13): : 3816 - 3826
  • [45] Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer
    Sun, Qinying
    Wei, Xiangzhen
    Wang, Zhonglin
    Zhu, Yan
    Zhao, Weiying
    Dong, Yuchao
    CANCERS, 2022, 14 (14)
  • [46] Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    Gao, J.
    Li, H. -R.
    Jin, C.
    Jiang, J. -H.
    Ding, J. -Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10): : 1287 - 1301
  • [47] Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
    Chhouri, Houssein
    Alexandre, David
    Grumolato, Luca
    CANCERS, 2023, 15 (02)
  • [48] Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    J. Gao
    H.-R. Li
    C. Jin
    J.-H. Jiang
    J.-Y. Ding
    Clinical and Translational Oncology, 2019, 21 : 1287 - 1301
  • [49] REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Yamauchi, Hiroyoshi
    Nakayama, Masayuki
    Yamamoto, Shinichi
    Saito, Tatsuya
    Okuyama, Akiko
    Mato, Naoko
    Yamasawa, Hideaki
    Suzuki, Takuji
    Bando, Masashi
    Hagiwara, Koichi
    RESPIROLOGY, 2017, 22 : 242 - 242
  • [50] Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer
    Fei Zhou
    Caicun Zhou
    Oncology and Translational Medicine, 2015, 1 (01) : 20 - 25
12345